VoCare raises $2.2 million for telehealth device
The local startup expects to raise another $1.3 million this year and launch pilots of a new mobile device connecting patients with doctors.
Health Care Businesses
Articles
Lilly wins reversal of class action in Zyprexa suit
A U.S. appeals court in New York threw out a September 2008 ruling that said plaintiffs could pursue as a group claims that Zyprexa marketing caused them to pay more for the drug than what it was worth. The plaintiffs were seeking $6.8 billion in damages.
Lilly investing up to $150M in VC funds
The three venture funds, which will focus on drug development, may be worth a total of $750 million, up to $250 million each, and Lilly will contribute as much as 20 percent of the money.
Poor economy keeping Wishard project costs down
Contractors starving for work are submitting more competitive bids, which so far has led to about $10 million in savings, hospital official says.
Indianapolis software firm RealMed acquired
Health care software firm RealMed Corp. will keep its base of operations in Indianapolis after being acquired by health information exchange provider Availity LLC of Jacksonville, Fla. Terms of the deal announced Wednesday were not disclosed.
Lilly wins ban of generic Strattera pending appeal
The U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday granted Lilly’s request to prevent sales until the court rules on a judge’s decision invalidating a patent on the medicine.
After health reform, Lilly looking for more
The health reform debate may have ended in Congress, but Eli Lilly and Co. remains active, sponsoring a talk about the positives of the
bill—and calling for further government efforts to help pharmaceutical research and development.
Health insurer cash shifts to favor Republicans before election
Health insurers led by WellPoint Inc. are backing Republicans with campaign donations by an 8-to-1 margin, favoring the party
that’s promised to repeal President Barack Obama’s health-care overhaul if it wins back Congress.
Lilly wins further delay in sales of Strattera copies
Strattera generated U.S. sales of $445.6 million last year, and each day that Lilly can fend off generic competition would
translate into an average $1.22 million in sales.
Endocyte’s $86M IPO plan a boon for Indiana, investors
Venture capitalists in Indiana and nationally have thrown money at the company with abandon. Local investors include CID Capital,
Clarian Health Ventures and the Indiana Future Fund.
Diabetes research pioneer Kirtley dies at 96
Diabetics who control their disease with pills instead of frequent insulin injections can thank Dr. William R. Kirtley, a
groundbreaking Eli Lilly researcher.
Lilly woes take notch out of debt rating
Even with debt levels at Eli Lilly and Co. at paltry lows, a string of bad news finally forced Standard & Poor’s
to lower
its rating on the company’s senior unsecured debt. But the New York-based agency said it believes the Indianapolis-based
drugmaker will eventually break its string of bad luck on developing new products.
Pearl IRB first firm in state to pre-screen clinical drug trials
Two former Eli Lilly and Co. employees launched the firm that promises to attract more clinical trial business to the state.
Lilly gains panel’s backing to expand Cymbalta use
Outside advisers to the Food and Drug Administration voted 8-6 Thursday in favor of a broader use of Cymbalta on the basis
of studies in lower back pain and osteoarthritis of the knee.
Lilly wins temporary ban on sales of Strattera copies
The invalidation of Lilly’s Strattera patent opened the door for as many as 10 companies to sell generic versions of the drug,
which generated U.S. sales of $445.6 million last year as a treatment for attention deficit hyperactivity disorder.
Cancer drug developer Endocyte files for IPO
The company, headquartered at Purdue Research Park, said the number of shares to be offered and their price range have yet
to be determined.
Lilly Alzheimer’s drug prospect only the latest to fail
A dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the
disease since 1906, have failed in mid- to late-stage testing since 2003.
Lilly’s Cymbalta helps chronic pain in U.S. review
Approval for the millions of Americans with chronic back or knee pain may add more than $500 million, or 16 percent, to Cymbalta’s
annual sales.
Lilly halts development of Alzheimer’s drug
Studies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical
giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through
2014.
Medco to acquire United BioSource for $710M
Medco operates an automated pharmacy and distribution center in Whitestown in Boone County, and it plans to employ more than
1,400 people there by 2012.